Dynamic Technology Lab Private Ltd Purchases New Position in COMPASS Pathways plc (NASDAQ:CMPS)

Dynamic Technology Lab Private Ltd acquired a new position in COMPASS Pathways plc (NASDAQ:CMPS) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 21,945 shares of the company’s stock, valued at approximately $83,000.

Several other institutional investors also recently bought and sold shares of CMPS. China Universal Asset Management Co. Ltd. bought a new position in shares of COMPASS Pathways during the 4th quarter worth $41,000. Wealthfront Advisers LLC bought a new position in COMPASS Pathways during the 4th quarter worth about $43,000. Flagship Harbor Advisors LLC purchased a new position in COMPASS Pathways during the 4th quarter valued at about $43,000. Conservest Capital Advisors Inc. raised its holdings in shares of COMPASS Pathways by 28.9% in the 4th quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company’s stock valued at $51,000 after purchasing an additional 3,000 shares in the last quarter. Finally, Simplify Asset Management Inc. purchased a new stake in shares of COMPASS Pathways in the 4th quarter worth approximately $54,000. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

COMPASS Pathways Trading Up 5.6 %

Shares of NASDAQ:CMPS opened at $2.85 on Friday. The business’s 50-day moving average is $3.57 and its 200 day moving average is $4.38. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. COMPASS Pathways plc has a 1 year low of $2.49 and a 1 year high of $9.63. The firm has a market capitalization of $264.12 million, a P/E ratio of -1.30 and a beta of 2.34.

COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.01). On average, research analysts predict that COMPASS Pathways plc will post -2.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Stifel Nicolaus assumed coverage on shares of COMPASS Pathways in a report on Thursday, February 27th. They set a “buy” rating and a $11.00 price objective on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $18.00 price target on shares of COMPASS Pathways in a research report on Wednesday, January 15th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of COMPASS Pathways in a research report on Friday, March 28th. HC Wainwright reiterated a “buy” rating and issued a $45.00 target price on shares of COMPASS Pathways in a research note on Tuesday, March 4th. Finally, Canaccord Genuity Group decreased their price target on shares of COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, February 28th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, COMPASS Pathways currently has a consensus rating of “Buy” and an average price target of $20.20.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.